HC Wainwright Weighs in on Fractyl Health FY2030 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Fractyl Health in a note issued to investors on Monday, January 26th. HC Wainwright analyst J. Pantginis forecasts that the company will earn $0.79 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share.

Several other research analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Canaccord Genuity Group restated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Friday, December 19th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Fractyl Health Trading Down 13.7%

Shares of NASDAQ:GUTS opened at $1.83 on Tuesday. The business has a 50-day moving average price of $2.01 and a 200 day moving average price of $1.53. The company has a market capitalization of $250.78 million, a price-to-earnings ratio of -0.80 and a beta of 1.62. Fractyl Health has a 12-month low of $0.82 and a 12-month high of $3.03.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Wednesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01).

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GUTS. Nantahala Capital Management LLC acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $19,298,000. Alyeska Investment Group L.P. purchased a new stake in shares of Fractyl Health during the third quarter worth $8,981,000. Rosalind Advisors Inc. acquired a new stake in shares of Fractyl Health in the third quarter valued at $7,950,000. Woodline Partners LP boosted its holdings in Fractyl Health by 821.1% in the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after purchasing an additional 4,908,693 shares during the period. Finally, General Catalyst Group Management LLC acquired a new position in Fractyl Health during the 2nd quarter worth $7,912,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.